L-phenylalanine mustard (L-PAM): the first 25 years.

Suppr

超能文献

作者信息

Furner R L, Brown R K

出版信息

Cancer Treat Rep. 1980 Apr-May;64(4-5):559-74.

PMID:7000345

Abstract

摘要

相似文献

L-phenylalanine mustard (L-PAM): the first 25 years.

Cancer Treat Rep. 1980 Apr-May;64(4-5):559-74.

Resistance patterns of Walker carcinosarcoma 256 and other rodent tumors to cyclophosphamide and L-phenylalanine mustard.

Cancer Res. 1980 Mar;40(3):830-3.

Cytotoxicities of the L and D isomers of phenylalanine mustard in L 1210 cells.

Biochem Pharmacol. 1979 Nov 1;28(21):3221-5. doi: 10.1016/0006-2952(79)90065-0.

Transport of melphalan by sensitive and resistant L1210 cells.

Cancer Res. 1980 Apr;40(4):1144-9.

Adriamycin. A new anticancer drug with significant clinical activity.

Ann Intern Med. 1974 Feb;80(2):249-59. doi: 10.7326/0003-4819-80-2-249.

DNA cross-linking as an indicator of sensitivity and resistance of mouse L1210 leukemia to cis-diamminedichloroplatinum(II) and L-phenylalanine mustard.

Cancer Res. 1981 Feb;41(2):640-9.

Enhancement of melphalan therapy with glutaminase:asparaginase.

Res Commun Chem Pathol Pharmacol. 1978 Oct;22(1):83-92.

Adjuvant chemotherapy with cyclophosphamide, methotrexate, and 5-fluorouracil, vincristine, and prednisone compared with single-agent L-phenylalanine mustard for patients with operable breast carcinoma and positive axillary lymph nodes: 20-year results of a Southwest Oncology Group study.

Cancer. 2003 Jan 1;97(1):21-9. doi: 10.1002/cncr.10982.

Relevance of the hydrolysis and protein binding of melphalan to the treatment of multiple myeloma.

Cancer Chemother Pharmacol. 1989;23(2):76-80. doi: 10.1007/BF00273521.

Melphalan resistance in myeloma.

Br J Haematol. 1986 May;63(1):1-6. doi: 10.1111/j.1365-2141.1986.tb07488.x.

引用本文的文献

Spotlight on Melphalan Flufenamide: An Up-and-Coming Therapy for the Treatment of Myeloma.

Drug Des Devel Ther. 2021 Jul 8;15:2969-2978. doi: 10.2147/DDDT.S295215. eCollection 2021.

Melflufen - a peptidase-potentiated alkylating agent in clinical trials.

Oncotarget. 2017 Jun 8;8(39):66641-66655. doi: 10.18632/oncotarget.18420. eCollection 2017 Sep 12.

In vitro and in vivo activity of melflufen (J1)in lymphoma.

BMC Cancer. 2016 Apr 4;16:263. doi: 10.1186/s12885-016-2299-9.

First-in-human, phase I/IIa clinical study of the peptidase potentiated alkylator melflufen administered every three weeks to patients with advanced solid tumor malignancies.

Invest New Drugs. 2015 Dec;33(6):1232-41. doi: 10.1007/s10637-015-0299-2. Epub 2015 Nov 10.

The novel alkylating prodrug J1: diagnosis directed activity profile ex vivo and combination analyses in vitro.

Invest New Drugs. 2008 Jun;26(3):195-204. doi: 10.1007/s10637-007-9092-1. Epub 2007 Oct 6.

Antitumor efficacy and acute toxicity of the novel dipeptide melphalanyl-p-L-fluorophenylalanine ethyl ester (J1) in vivo.

Invest New Drugs. 2004 Nov;22(4):411-20. doi: 10.1023/B:DRUG.0000036683.10945.bb.

Structural characterization of melphalan modified 2'-oligodeoxynucleotides by miniaturized LC-ES MS/MS.

J Am Soc Mass Spectrom. 2004 Apr;15(4):568-79. doi: 10.1016/j.jasms.2003.12.005.

Tissue distribution and macromolecular interactions of 14[C-ring] melphalan in the rat.

Cancer Chemother Pharmacol. 1982;8(3):271-6. doi: 10.1007/BF00254049.

Increased cancericidal activity of PTT.119; a new synthetic bis-(2-chloroethyl)amino-L-phenylalanine derivative with carrier amino acids. II. In vivo bioassay.

Cancer Chemother Pharmacol. 1984;12(2):77-82. doi: 10.1007/BF00254593.

The effect of radiosensitizers on the pharmacokinetics of melphalan and cyclophosphamide in the mouse.

Br J Cancer. 1983 Sep;48(3):375-83. doi: 10.1038/bjc.1983.202.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验